e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

12.46 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

7 Stocks 'On Sale' This Holiday Season ↗

November 26, 2021

The SPDR S&P 500 ETF Trust (NYSE: SPY) has generated a total return of 26.4% year-to-date, but much of those overall gains have been driven by a handful of megacap stocks. In...

Via Benzinga

Topics Stocks

3 Pharma Stocks That Are Too Cheap to Ignore ↗

November 25, 2021

Many stocks are ridiculously expensive right now -- but not these three.

Via The Motley Fool

Novartis May Have Buyer(s) For Its Sandoz Unit - Report ↗

November 23, 2021

According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the Novartis AG...

Via Benzinga

New Alternatives for Branded Biologics ↗

November 22, 2021

We’ve all heard about generic drugs. They are time-tested and battle-proven medicines that are more affordable than their patented predecessors. Branded drugs consistently...

Via Benzinga

7 Stocks to Buy for Their Resistance to the 6.2% Monthly Inflation ↗

November 22, 2021

These companies either have no exposure to inflation or have strong branding and customer loyalty, enabling them to pass higher costs.

Via InvestorPlace

Unusual Options Activity Insight: Viatris ↗

August 09, 2021

On Monday, shares of Viatris (NASDAQ:VTRS) saw unusual opt...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

3 Things About Viatris That Smart Investors Know ↗

November 21, 2021

Don't expect it to follow the trajectory of a hot growth stock.

Via The Motley Fool

Johnson & Johnson Pops As It Announces The Biggest Split In Health Care ↗

November 12, 2021

Johnson & Johnson will split its consumer health unit into a publicly traded company.

Via Investor's Business Daily

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

Earnings Scheduled For November 8, 2021 ↗

November 08, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...

Via Benzinga

Could Viatris Stock Help You Retire a Millionaire? ↗

October 23, 2021

It depends on how much help you're looking for.

Via The Motley Fool

Topics Retirement

3 No-Brainer Biotech Stocks to Buy Right Now ↗

October 16, 2021

Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Viatris should have plenty of room to run.

Via The Motley Fool

2 Ultra-Cheap Stocks Trading Below Their Book Values ↗

October 07, 2021

And these stocks also pay relatively high dividends.

Via The Motley Fool

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Viatris Inc. and Encourages Investors who Formerly Held Shares of Mylan Inc. (MYL) to Contact the Firm

September 29, 2021

From The Schall Law Firm

Via Business Wire

Why Are Theravance Bio Shares Plummeting Premarket Today? ↗

September 15, 2021

Theravance Biopharma Inc (NASDAQ: TBPH) will reduce its headcount by approximately 75% (estimated 270 positions), with most of the lay off to complete in November...

Via Benzinga

Why Wall Street Thinks This Dirt Cheap Value Stock Could Soar ↗

September 13, 2021

It's kind of a boring stock. But analysts think that it could deliver not-so-boring growth.

Via The Motley Fool

Got $5,000? These 2 Dividend Stocks Are Dirt Cheap Buys ↗

September 02, 2021

And their yields are both over 3%.

Via The Motley Fool

3 Things About Pfizer That Smart Investors Know ↗

August 31, 2021

They're all about the future.

Via The Motley Fool

Theravance Stock Crashes; Can Longer Testing Salvage Its J&J-Partnered Drug? ↗

August 24, 2021

Theravance said late Monday its ulcerative colitis treatment failed in midstage testing, and the biotech stock plummeted early Tuesday.

Via Investor's Business Daily

3 Top Biotech Stocks to Buy in August ↗

August 17, 2021

Each of these companies makes for a great vehicle to play an aging demographic.

Via The Motley Fool

Analysts Love This Newly Formed Healthcare Company; Should You? ↗

August 16, 2021

Viatris' steady operating results and cheap valuation are two key reasons for its high one-year price target.

Via The Motley Fool

Viatris Inc (VTRS) Q2 2021 Earnings Call Transcript ↗

August 09, 2021

VTRS earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

How This Historic FDA Approval Benefits Viatris ↗

August 04, 2021

Here's what the FDA's approval of Semglee, from Viatris and Biocon, means for the former.

Via The Motley Fool

Viatris Stock Gains After FDA Approves Viatris-Biocon Biologics' Insulin Glargine Biosimilar Injection ↗

July 29, 2021

The FDA cleared Viatris inc (NASDAQ: VTRS) - Biocon Biologics' Semglee insulin glargine-yfgn injection as a biosimilar. Semglee indicates controlling high...

Via Benzinga

Earnings Scheduled For August 9, 2021 ↗

August 09, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...

Via Benzinga

The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗

July 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

How To Find Value Stocks July 2021 ↗

July 21, 2021

Identifying fair value in an inflated stock market is really important, because in all markets, whether bull or bear you can always find value.

Via Talk Markets

10 Worst Performing S&P 500 Stocks Of 2021 ↗

July 02, 2021

The S&P 500 has continued its late-2020 momentum in the first two quarters of the year, gaining more than 15% year-to-date. Most U.S. investors have had a lot of winners in...

Via Benzinga

Topics Stocks

The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO ↗

June 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy